37 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
Free University of Brussels
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.
Merck Sharp and Dohme Research Laboratories
Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
Free University of Brussels
Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.
Pfizer
Inhibition of myeloperoxidase: evaluation of 2H-indazoles and 1H-indazolones.
University of California
Biologically active eremophilane-type sesquiterpenes from Camarops sp., an endophytic fungus isolated from Alibertia macrophylla.
Universidade Estadual Paulista
Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors.
Free University of Brussels
Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening.
Free University of Brussels
Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification.
Free University of Brussels
Structure-based design, synthesis, and pharmacological evaluation of 3-(aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors.
Universite£? Libre De Bruxelles
Design, synthesis, and biological activity studies on benzimidazole derivatives targeting myeloperoxidase.
Izmir Katip Celebi University
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
Astrazeneca
Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO).
Bristol-Myers Squibb
Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
Bristol Myers Squibb
Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO).
Novartis Institutes For Biomedical Research
Potent Triazolopyridine Myeloperoxidase Inhibitors.
Bristol-Myers Squibb Research and Development
The development of myeloperoxidase inhibitors.
University Sarajevo School of Science and Technology
Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase.
Emory University
Improvements in the minimum binding sequence of C5a: examination of His-67.
Abbott Laboratories
Novel benzothiophene-, benzofuran-, and naphthalenecarboxamidotetrazoles as potential antiallergy agents.
Warner-Lambert
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
Mission Therapeutics
Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
Merck Sharp & Dohme
HYPDH inhibitors and methods of use for the treatment of kidney stones
Wake Forest University Health Sciences
(Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders
Hoffmann-La Roche
Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.
Karlsruhe Institute of Technology
Carbamate/urea derivatives containing piperidin and piperazin rings as H3 receptor inhibitors
Novartis
7-membered ring compound and method of production and pharmaceutical application thereof
Daiichi Sankyo